From the George Institute for International Health, University of Sydney, Sydney (J.C.); and the Baker IDI Heart and Diabetes Institute, Melbourne (M.E.C.) — both in Australia.
Dr. Chalmers reports serving on an advisory board for Servier and receiving lecture fees from Servier, Pfizer, and Daiichi and grant support from Servier; and Dr. Cooper, receiving consulting fees from Merck, GlaxoSmithKline, Amgen, and AstraZeneca and lecture fees from Servier. No other potential conflict of interest relevant to this article was reported.
